Pregabalin In Partial Seizures: An Open-Label, International, Multicenter Add-On Therapy Trial.
NCT ID: NCT00141427
Last Updated: 2021-01-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
540 participants
INTERVENTIONAL
2004-11-30
2006-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pregabalin In Partial Seizures (PREPS): An Open-Label, Multicenter Add On Therapy Trial
NCT00407797
Pregabalin Open-Label Extension Trial in Patients With Partial Seizures
NCT00143143
Pregabalin In Partial Seizures Extension Study
NCT00143130
Once-A-Day Pregabalin For Partial Seizures
NCT01262677
To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures
NCT00141388
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pregabalin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18 years and older.
Exclusion Criteria
* Having a progressive neurological or systemic disorder
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Bruges, , Belgium
Pfizer Investigational Site
Brussels, , Belgium
Pfizer Investigational Site
Duffel, , Belgium
Pfizer Investigational Site
Ghent, , Belgium
Pfizer Investigational Site
Leuven, , Belgium
Pfizer Investigational Site
Liège, , Belgium
Pfizer Investigational Site
Tielt, , Belgium
Pfizer Investigational Site
Yvoir, , Belgium
Pfizer Investigational Site
Helsinki, , Finland
Pfizer Investigational Site
Kuopio, , Finland
Pfizer Investigational Site
Tampere, , Finland
Pfizer Investigational Site
Marseille, Cedex 05, France
Pfizer Investigational Site
Montpellier, Cedex 5, France
Pfizer Investigational Site
Lyon, Cedex, France
Pfizer Investigational Site
Bayonne, , France
Pfizer Investigational Site
Bordeaux, , France
Pfizer Investigational Site
Grenoble, , France
Pfizer Investigational Site
Lille, , France
Pfizer Investigational Site
Marseille, , France
Pfizer Investigational Site
Nancy, , France
Pfizer Investigational Site
Nice, , France
Pfizer Investigational Site
Paris, , France
Pfizer Investigational Site
Paris, , France
Pfizer Investigational Site
Paris, , France
Pfizer Investigational Site
Rennes, , France
Pfizer Investigational Site
Strasbourg, , France
Pfizer Investigational Site
Toulouse, , France
Pfizer Investigational Site
Tours, , France
Pfizer Investigational Site
The Hague, South Holland, Netherlands
Pfizer Investigational Site
Alkmaar, , Netherlands
Pfizer Investigational Site
Breda, , Netherlands
Pfizer Investigational Site
Heeze, , Netherlands
Pfizer Investigational Site
Hilversum, , Netherlands
Pfizer Investigational Site
Oss, , Netherlands
Pfizer Investigational Site
Southwest Heemstede, , Netherlands
Pfizer Investigational Site
Katowice, , Poland
Pfizer Investigational Site
Krakow, , Poland
Pfizer Investigational Site
Lublin, , Poland
Pfizer Investigational Site
Warsaw, , Poland
Pfizer Investigational Site
Warsaw, , Poland
Pfizer Investigational Site
Warsaw, , Poland
Pfizer Investigational Site
Wroclaw, , Poland
Pfizer Investigational Site
Braga, , Portugal
Pfizer Investigational Site
Funchal, , Portugal
Pfizer Investigational Site
Lisbon, , Portugal
Pfizer Investigational Site
Matosinhos Municipality, , Portugal
Pfizer Investigational Site
Ponta Delgada, , Portugal
Pfizer Investigational Site
Porto, , Portugal
Pfizer Investigational Site
Lausanne, , Switzerland
Pfizer Investigational Site
Zurich, , Switzerland
Pfizer Investigational Site
Zurich, , Switzerland
Pfizer Investigational Site
Cambridge, Cambs, United Kingdom
Pfizer Investigational Site
Truro, Cornwall, United Kingdom
Pfizer Investigational Site
Plymouth, Devon, United Kingdom
Pfizer Investigational Site
Glasgow, , United Kingdom
Pfizer Investigational Site
Oxford, , United Kingdom
Pfizer Investigational Site
, ,
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A0081005
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.